ABEO:NSD-Abeona Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.23

Change

-0.06 (-4.65)%

Market Cap

USD 0.12B

Volume

0.63M

Avg Analyst Target

USD 5.00 (+306.50%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+39.90 (+11.51%)

USD141.98B 237.00 190.09
BNTX BioNTech SE

+11.60 (+3.41%)

USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

+9.38 (+1.63%)

USD61.22B 16.36 12.83
VRTX Vertex Pharmaceuticals Incorpo..

+1.73 (+0.87%)

USD52.23B 26.58 13.36
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
GMAB Genmab A/S

+1.09 (+2.41%)

USD29.62B 33.28 3.77
BGNE BeiGene, Ltd

+14.03 (+4.29%)

USD29.25B N/A N/A
SGEN Seagen Inc

+3.95 (+2.56%)

USD27.91B 47.87 38.34
RPRX Royalty Pharma plc

+0.47 (+1.26%)

USD23.19B 31.49 13.92
ALNY Alnylam Pharmaceuticals, Inc

+0.85 (+0.48%)

USD21.03B N/A N/A

ETFs Containing ABEO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.66% 40% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.66% 40% F 17% F
Trailing 12 Months  
Capital Gain -57.88% 11% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.88% 11% F 4% F
Trailing 5 Years  
Capital Gain -66.12% 28% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.12% 28% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain 10.92% 47% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.92% 46% F 52% F
Risk Return Profile  
Volatility (Standard Deviation) 103.73% 26% F 15% F
Risk Adjusted Return 10.53% 39% F 28% F
Market Capitalization 0.12B 25% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.89 29% F 38% F
Price/Book Ratio 1.47 85% B 72% C-
Price / Cash Flow Ratio -3.53 29% F 61% D-
EV/EBITDA 0.13 75% C 96% A
Management Effectiveness  
Return on Equity -52.91% 52% F 28% F
Return on Invested Capital -34.31% 64% D 21% F
Return on Assets -20.78% 57% F 17% F
Debt to Equity Ratio 1.39% 76% C 86% B
Technical Ratios  
Short Ratio 3.40 52% F 39% F
Short Percent 5.25% 58% F 37% F
Beta 1.39 47% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.